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Aims To investigate the long-term performance of the CONFIRM score for prediction of all-cause mortality in a large patient
cohort undergoing coronary computed tomography angiography (CCTA).
Methods
and results
Patients with a 5-year follow-up from the international multicentre CONFIRM registry were included. The primary end-
point was all-cause mortality. The predictive value of the CONFIRM score over clinical risk scores (Morise, Framing-
ham, and NCEP ATP III score) was studied in the entire patient population as well as in subgroups. Improvement in risk
prediction and patient reclassification were assessed using categorical net reclassification index (NRI) and integrated
discrimination improvement (IDI). During a median follow-up period of 5.3 years, 982 (6.5%) of 15 219 patients
died. The CONFIRM score outperformed the prognostic value of the studied three clinical risk scores (c-indices: CON-
FIRM score 0.696, NCEP ATP III score 0.675, Framingham score 0.661, Morise score 0.606; c-index for improvement
CONFIRM score vs. NCEP ATP III score 0.650, P, 0.0001). Application of the CONFIRM score allowed reclassifica-
tion of 34% of patients when compared with the NCEP ATP III score, which was the best clinical risk score. Reclassi-
fication was significant as revealed by categorical NRI (0.06 with 95% CI 0.02 and 0.10, P ¼ 0.005) and IDI (0.013 with
95% CI 0.01 and 0.015, P, 0.001). Subgroup analysis revealed a comparable performance in a variety of patient
subgroups.
Conclusions The CONFIRM score permits a significantly improved prediction of mortality over clinical risk scores for.5 years after
CCTA. These findings are consistent in a large variety of patient subgroups.
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Introduction
Nowadays coronary computed tomography angiography (CCTA) is
a clinically widely used tool for patients with suspected coronary ar-
tery disease (CAD) and a low-to-intermediate pre-test probability
providing anatomical information at reasonable radiation dose le-
vels.1 – 3 Beside its utility for the detection and exclusion of CAD,
CCTA findings correlate with clinical outcome.4 – 8 In comparison
to other diagnostic tools for the investigation of suspected CAD,
CCTA is able to visualize beginning atherosclerotic vessel altera-
tions earlier compared with other non-invasive imaging modalities
and therefore might be able to identify patients at higher risk earl-
ier.9 Various approaches to identify high-risk patients based on
CCTA findings have been proposed so far, mainly focussing on cor-
onary artery disease burden, luminal obstruction degree, and plaque
composition.4 –7,10
Recently, a score combining established clinical risk parameters
and the presence of non-obstructive proximal mixed or calcified
plaques as well as proximal lumen narrowing of ≥50% was devel-
oped from the CONFIRM (COronary CT Angiography EvaluatioN
For Clinical Outcomes: An InteRnational Multicenter) population.4
This score significantly improved prediction of all-cause mortality
over clinical risk scores alone. However, the analysis was limited
to a follow-up period of 2.3 years, and the mortality rate was low.
Accordingly, the objective of this study was to investigate whether
the improved risk prediction can be extended to a longer follow-up
period and whether the predictive value is maintained in certain pa-




The CONFIRM registry is an international, multicentre, observational
registry collecting clinical, procedural, and follow-up data of patients
undergoing CCTA for clinically indicated reasons.11 Patients were en-
rolled at 21 participating study sites in nine countries (Austria, Canada,
Germany, Israel, Italy, Portugal, South Korea, Switzerland, and the USA).
Institutional review board approval was obtained at each centre. Our
analysis included all patients from the CONFIRM registry with sus-
pected but not proven CAD, of whom luminal stenosis as well as pres-
ence and composition of plaque in CCTA on a segment-basis was
reported, and a 5-year follow-up was available. The exclusion criterion
of known CAD was defined as patient reported past myocardial infarc-
tion, coronary revascularization, or the presence of any stents or grafts/
graft stenosis as recorded by CT findings.
For every patient, a structured interview was conducted prior to
CCTA to collect information on symptoms attributable to cardiac dis-
ease and the presence of cardiovascular risk factors. Diabetes mellitus
was defined by diagnosis of a physician and/or the use of insulin or
oral antidiabetic medication. Systemic arterial hypertension was defined
as a documented history of blood pressure .140 mm Hg or treatment
with antihypertensive medications. A positive smoking history was de-
fined as current smoking or cessation of smoking within 3 months of
CCTA. A positive family history of CAD was defined as history of myo-
cardial infarction of a first-degree relative below the age of 55 years for
male and 65 years for female relatives. In addition, blood cholesterol le-
vels of the lipid test nearest to the index examination were recorded.
From these data, the National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults (Adult Treatment Panel III) (NCEP ATP III) score, the
Framingham risk score, and the Morise clinical risk score were
calculated.12–14
Image acquisition and analysis
The imaging protocols adhered to the Society of Cardiovascular Com-
puted Tomography guidelines on appropriateness and performance of
CCTA, as far as available at the time of scanning.15 –17 Patient prepar-
ation, data acquisition, and analysis were executed as established at
the local study sites. CCTA investigations were performed on
multiple-row detector CT scanners with at least 64 simultaneously ac-
quired slices.
The presence of coronary artery plaque and degree of luminal ob-
struction were assessed visually at the local study sites using a
16-segment coronary artery model.18 Coronary plaques were classified
as non-calcified, calcified, or mixed for each coronary artery segment.
Calcified plaques were defined as any visible calcification in CCTA da-
tasets. Non-calcified plaques were defined as a tissue structure of at
least 1 mm2 that could be clearly discriminated from the vessel lumen
and surrounding tissue with a density below the contrast-enhanced
Table 1 Baseline characteristics
Number of patients, n 15 219
Age 58.7+12.8
BMI (kg/m2) 27.6+5.1
Male sex, n (%) 8515 (55.9)
Arterial hypertension, n (%) 8318 (54.7)
Hyperlipoproteinemia, n (%) 8445 (55.5)
Total cholesterol (mg/dL) 194+45
LDL-cholesterol (mg/dL) 116+37
HDL-cholesterol (mg/dL) 53+17
Diabetes, n (%) 2618 (17.2)
Positive family history for CAD, n (%) 6120 (40.2)
Active smoker, n (%) 3284 (21.6)
Statin treatment 2475 (36.1)
Aspirin treatment 2521 (36.9)
Angina pectoris
Non-anginal chest pain 2091 (15.4)
Atypical Angina 4706 (34.6)
Typical Angina 3800 (27.9)
Values are means with SD or numbers (%). Information about medical treatment at
baseline was recorded in 6825 (Aspirin) and 6858 (statins) patients.
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blood pool. Plaques meeting both the criteria for calcified and non-
calcified plaques were classified as mixed plaques. Luminal obstruction
was graded for each segment as none, mild (1–49%), moderate (50–
69%), and severe (70% or more). For the CONFIRM score, the degree
of luminal obstruction was dichotomized to obstruction ,50% or 50%
and above.
The segment-stenosis score and segment-involvement score were
calculated as proposed by Min et al. and the adapted Leaman score
was calculated as proposed by Goncalves et al.7,19
Follow-up and study endpoint
The endpoint of the study was time to death from any cause. In U.S.
sites, death status was ascertained by querying the Social Security Death
Index. In non-U.S. sites, follow-up data were collected by mail or tele-
phone contact with the patients or their families; events were verified
by hospital records or contacts with the attending physician.
CONFIRM Score
The score was initially modelled based on a test sample of 17 793 pa-
tients and a validation sample of 2506 patients. Three parameters are
incorporated into the score. To integrate the clinical risk, the NCEP
ATP III score is included. Furthermore, the number of proximal seg-
ments containing calcified or mixed plaques and the number of proximal
segments containing a stenosis of at least 50% luminal obstruction ob-
tained from the CCTA scans are included. Proximal segments included
left main coronary artery, proximal and mid left anterior descending ar-
tery, proximal left circumflex artery, first obtuse marginal branch, and
the proximal and mid right coronary artery. The detailed process is de-
scribed elsewhere.4
Statistical analysis
Categorical variables are expressed as frequencies and percentages;
continuous variables are expressed as mean+ standard deviation
(SD) or median with interquartile ranges as appropriate. All statistical
evaluations are based on survival with the Kaplan–Meier method; haz-
ard ratios (HRs) in continuous variables refer to 75th and 25th percent-
ile values and like multivariable analyses were calculated with the
Cox proportional hazard model. c-indexes were calculated from
time-to-event data as proposed by Harrell et al.20 c-index for improve-
ment was calculated analogously using the first test as reference instead
of a random guess as in standard c-statistics. To assess reclassification,
categorical net reclassification improvement (NRI) and integrated dis-
crimination improvement (IDI) were calculated based upon the risk cat-
egories of the NCEP ATP III score. The statistical package R (version
2.10.1) including the package rms was used for statistical analysis.21
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Table 2 Performance of clinical risk scores for the prediction of all-cause mortality
Score Survival (n5 14 237) Death (n5 982) Hazard ratio [95% CI] x2 c-index P-value
NCEP ATP III 9.8+8.8 15.6+11.2 1.76 [1.67; 1.86] 421 0.675 ,0000.1
Low risk 8316 (58.4) 333 (33.9)
Intermediate risk 2874 (20.2) 233 (23.7)
High risk 3047 (21.4) 416 (42.4)
Framingham risk 14.3+11.2 20.7+15.9 1.51 [1.44; 1.58] 276 0.661 ,0000.1
Low risk 6226 (44.1) 306 (31.3)
Intermediate risk 4730 (33.5) 263 (26.9)
High risk 3163 (22.4) 409 (41.8)
Morise 11.7+3.3 13+3.1 1.64 [1.51; 1.77] 149 0.606 ,0000.1
Low risk 2385 (16.8) 63 (6.4)
Intermediate risk 10 103 (71) 705 (71.8)
High risk 1749 (12.3) 214 (21.8)
Values are mean with SD or numbers (%). Hazard ratios were calculated for the 75th and 25th percentile.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Predictive value of the components integrated into the CONFIRM score
CONFIRM score component Survival





x2 Univariate model Multivariate model
c-index P-value c-index P-value




0.7+0.9 1.1+0.9 2.34 [2.04; 2.68] 147 0.691 ,0.0001 0.566 ,0.0001
Proximal segments containing
.50% luminal obstruction
0.4+0.7 0.8+0.9 1.51 [1.41; 1.63] 126 0.684 ,0.0001 0.535 0.0021
The multivariate model was corrected for clinical risk according to the NCEP ATP III score.
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Results
A 5-year follow-up was available in 17 179 patients enrolled at 21
participating centres. Of those, 1525 had to be excluded because
of known CAD and 435 patients had to be excluded because of
missing information about stenosis severity or plaque composition.
The final study population comprised 15 219 patients (55.9% males),
of which 10 186 belonged to the test or validation sample of the
initial study population used for modelling the score. Five thousand
and thirty-three additional patients were enrolled at seven centres
which joined the CONFIRM consortium at a later time point.4 Ana-
lysis is based on 75 250 cumulative patient years.
Mean patient age was 58.7+ 12.8 years. The dominating cardio-
vascular risk factors were arterial hypertension (54.7%) and hyper-
lipoproteinemia (55.5%). Information about statin and aspirin
treatment at the time of CCTA acquisition was recorded in 6858
(45.1%) and 6825 (44.9%), respectively. All baseline characteristics
are presented in Table 1. The pre-test risk was predominately low
when assessed with the NCEP ATP III score or Framingham score
and predominately intermediate when the Morise score was calcu-
lated (see also Table 2). During a median follow-up period of 5.3
[4.6; 5.9] years, 982 patients died, corresponding to an annual event
rate of 1.3% (95% confidence intervals (CIs) 1.2 and 1.4%).
Predictive value of clinical risk scores
All three clinical risk scores significantly correlated with all-cause
mortality (Table 2). The NCEP ATP III score performed best
(c-index 0.675), followed by the Framingham score (c-index
0.661) and the Morise score (c-index 0.606).
Predictive value of CCTA findings
Both the presence of any proximal non-obstructive calcified or
mixed plaque and the presence of any proximal stenosis correlated
significantly with clinical outcome (c-index 0.691 and 0.684, respect-
ively, see also Table 3). Hazard ratios were 2.34 (95% CI 2.04 and
2.68) for proximal non-obstructive calcified or mixed plaques and
1.51 (95% CI 1.41 and 1.63) for any proximal stenosis. The predic-
tion of all-cause mortality remained significant for both CCTA para-
meters after correction for clinical risk according to the NCEP ATP
III score (c-index for improvement 0.566, P, 0.0001 and c-index for
improvement 0.535, P, 0.01). Kaplan–Meier curves adjusted for
clinical risk are presented in Figure 1.
Figure 1 Risk-adjusted survival probability for the number proximal segments containing mixed or calcified plaques (left) and stenosis .50%
(right). The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) score was used for risk adjustment.
Figure 2 Receiver-operating characteristics curves of three clin-
ical risk scores (Morise score, Framingham score, and NCEP ATP
III score) and the CONFIRM score for all-cause mortality. NCEP
ATP III depicts National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III).
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Predictive value of the CONFIRM score
and risk reclassification
The CONFIRM score combining clinical risk factors and CCTA para-
meters revealed the best correlation with all-cause mortality (c-index
0.696, HR 2.86 with 95% CI 2.58 and 3.18). When comparing
c-indexes, the prediction of all-cause mortality was significantly better
with the CONFIRM score compared with NCEP ATP III score
(c-index for improvement 0.650, P, 0.0001, see also Figure 2).
The CONFIRM score provided a significantly better prediction of
all-cause mortality in comparison to CCTA-based risk scores
(c-indices for segment-stenosis score, segment-involvement score,
and Leaman score were 0.653, 0.648, and 0.646, respectively, P,
0.001 for comparison of all scores to the CONFIRM score).
Using the CONFIRM score, a large proportion of patients (34%)
could be reclassified regarding their 5-year mortality risk in com-
parison to the NCEP ATP III score. Categorical NRI (0.06 with
95% CI 0.02 and 0.10, P ¼ 0.005) and IDI (0.013 with 95% CI 0.01
Figure 3 Reclassification tables comparing the CONFIRM and National Cholesterol Education Program Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) score (NCEP ATP III score) in patients, who survived during follow-
up, died during follow-up and combined. Light blue and light green shading indicate upward and downward risk reclassification with the CONFIRM
score, respectively.
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and 0.015, P, 0.001) proved that reclassification was significant.
Reclassification for the entire population is shown in Figure 3.
Subgroup analysis
Figure 4 provides the subgroup analysis including all HR with 95% CI.
The subgroup analysis revealed a comparable performance of the
CONFIRM score in women (HR 2.8 with 95% CI 2.45 and 3.21)
and men (HR 2.83 with 95% CI 2.46 and 3.25) and in asymptomatic
(HR 3.15 with 95% CI 2.62 and 3.80) and symptomatic patients (HR
2.99 with 95% CI 2.55 and 3.52). Moreover, the score seems to be
particularly useful in older patients and patients with a higher NCEP
ATP III score.
Categorical NRI and IDI revealed a significant risk reclassification
in diabetic patients (P, 0.001 for both), patients with hypertension
(P, 0.01 for categorical NRI and P ¼ 0.04 for IDI), patients with hy-
perlipoproteinemia (P, 0.01 for both), active smokers (P, 0.01
for both), and patients with a positive family history (P, 0.001
for both) as well as for patients on aspirin (P, 0.01 for categorical
NRI and P ¼ 0.01 for IDI) and statin treatment (P, 0.01 for cat-
egorical NRI and P ¼ 0.04 for IDI).
In patients on statin treatment at baseline, 19.4% of patients
could be upgraded to a higher risk group and 14.2% of patients
were downgraded to a lower risk group with the use of the CON-
FIRM score, while 22.9% of patients and 6.8% without statin
Figure 4 Predictive value of the CONFIRM score in subgroups. Hazard ratios are provided for comparison of the 25th and 75th percentile and
presented with 95% CIs.
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treatment at baseline could be upgraded or downgraded, respect-
ively (Figure 5).
Discussion
The current study demonstrates that the CONFIRM score, which
incorporates the clinical risk profile and CCTA findings, significantly
correlates with all-cause mortality in a large cohort of patients with
5-year follow-up. Furthermore, the results prove that CCTA find-
ings can add incremental prognostic value to patient risk stratifica-
tion in comparison to clinical risk scores alone. Similar findings
have been published before, but were obtained from smaller single-
centre investigations.5,22,23 To our knowledge, this analysis is the
first to compare a risk score based upon clinical risk factors and
CCTA findings to traditional clinical risk scores in such a large co-
hort of patients with 5-year follow-up.
The unique strength of CCTA compared with other non-invasive
imaging modalities is the provided anatomical information, which al-
lows for the detection of atherosclerosis at earlier disease stages.9
Thus, it is not surprising that patients without any atherosclerotic
changes in CCTA have a very favourable prognosis.5,7 In addition,
a high negative predictive value for the exclusion of CAD has
been reported for CCTA.2 Consequently, CCTA has been recur-
rently proposed as a gatekeeper for invasive coronary angiography
to avoid unnecessary invasive procedures.8,24,25
The study reveals that approximately one-third of the patients
could be reclassified to a different risk group when the CONFIRM
score is used instead of the NCEP ATP III score, which has been iden-
tified as the best traditional risk score in the current very large patient
population. The subgroup analysis indicates that the predictive value
of the CONFIRM score is higher in older patients and patients with a
higher overall clinical risk assessed by the NCEP ATP III score.
The results of the present study facilitate the hypothesis of
an additive predictive value of CCTA for a more customized patient
management, e.g. more rigorous medical treatment of cardiovascular
risk factors such as diabetes or arterial hypertension in high-risk pa-
tients. So far, evidence in this field is rare. The FACTOR 64 trial inves-
tigated benefits of a more aggressive therapy regimen in patients with
diabetes based upon CCTA findings in 900 patients in a prospective
fashion.26 Within 4 years, the combined primary endpoint of all-cause
mortality, non-fatal MI, and unstable angina occurred in 28 patients in
the CCTA group and in 34 patients in the control group (P ¼ 0.38) in
their study. However, at baseline .70% of patients in both groups
were already on statin therapy which is a limitation for CCTA guided
more aggressive medical therapy regimens. The SCOT-HEART trial
randomized 4146 patients with angina suspected to be caused by
CAD to a standard care or a standard care plus CCTA group. After
1.7 years, the occurrence of myocardial infarction was 38% lower in
the CCTA group (26 vs. 42 patients). Findings barely missed statistical
significance (P ¼ 0.053).27 However, in a substudy from the
SCOT-HEART trial recently published by Williams et al. the occur-
rence of fatal and non-fatal myocardial infarction was significantly low-
er (17 vs. 34, P ¼ 0.02) when early events occurring within the first 50
days after randomization were excluded.28 Those findings underline
the ongoing necessity to effectively translate the predictive power
of CCTA in a benefit for patients in daily clinical practise.
Although there is strong evidence that statin treatment can re-
duce the occurrence of adverse cardiovascular events and mortality
in patients with proven CAD, statin treatment is not incorporated
into major clinical risk scores such as the NCEP ATP III score, Fra-
mingham score, or Morise score which were used in our study.29,30
However, our results prove that the additive predictive value of
CCTA is maintained in both patients with and without statin treat-
ments. Our subgroup analysis of patients on statin treatment further
indicates that CCTA’s usefulness is not limited to the identification
of patients, who benefit from statin treatment, but also might be
useful to identify patients, who do not benefit from statin treatment.
Those findings are in line with the above cited substudy from the
SCOT-HEART trial by Williams et al.28 Their analysis revealed
that preventive treatment was significantly more often initiated in
the CCTA group (293 vs. 84, P, 0.001), but was also significantly
more often cancelled in the CCTA group (77 vs. 8, P, 0.001).
The present study has several strengths but also a few limitations.
Strengths are the large number of patients analysed, the multicentre
design, the long follow-up period with .75 000 cumulative patient
years, the analysis of a large variety of subgroups and the use of a
hard endpoint. Most limitations are based on the observational de-
sign of the CONFIRM registry. Information about lifestyle changes,
medical therapy, or myocardial revascularization procedures based
upon CCTA findings is very limited and might have had significant
effects on patient outcome.
Conclusion
The present patient population undergoing CCTA for suspected
CAD is the largest population with a 5-year follow-up allowing a ro-
bust analysis of predictors for all-cause mortality. The CONFIRM
score, which incorporates the clinical risk profile as well as CCTA
findings, confirms that CCTA carries incremental prognostic infor-
mation over established clinical risk scores. In addition, the CON-
FIRM score permits effective reclassification of patients to clinical
risk categories. The improvement in risk prediction has been
Figure 5 Reclassification comparing the CONFIRM and Nation-
al Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) score (NCEP ATP III score) in patients
with and without statin treatment at baseline. Light blue and light
green shading indicate upward and downward risk reclassification
with the CONFIRM score, respectively. Information about statin
treatment at baseline was available in 6858 patients.
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established for a variety of different patient subgroups and is inde-
pendent of aspirin and statin treatment at baseline.
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